• 150+

    The UK’s most active investor in UK university spin-outs

  • £400M

    Over £400m raised; invested into over 150 companies

  • 25+ wins

    Award winning manager with track record of delivering returns

  • £1.4Bn

    Part of FTSE 250 sector specialist group with £1.4bn net assets

About Parkwalk

Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.

Performance

We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.

Learn More

Meet the Parkwalk team

Combining our diverse range of skills and experience with integrity and transparency the Parkwalk team has an outstanding track record for supporting high-growth innovation that delivers returns.

Harriet Doherty
Chloe Woodacre
Olivia Goodchild
Meet the team

Empowering Innovation

Parkwalk Funds invest in dynamic university spin-out companies seeking to commercialise intellectual property and technology. From investing in seed to later stage companies, we help fantastic management teams develop and build world-class successful businesses.

Cambridge Photon Technology

Cambridge Photon Technology (‘CPT’) is developing photon multiplier film technology, which increases the power output of silicon photovoltaic products significantly.

Mode Diagnostics

Mode is exploiting the electrochemical properties of biomarkers to produce novel assays for home diagnostic purposes. The company has developed a suite of technologies comprising assay development techniques, biosensing capabilities, microfabrication, electronics and wireless communications. Mode’s first product represents an evolution in bowel cancer screening, offering significant improvements

Sphere Fluidics

Sphere Fluidics picodroplet technology makes it possible to encapsulate and screen millions of individual cells or biological molecules in a single day. Its CytoMine proprietary microfluidic technology allows the ultra-high throughput analysis of isolated cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pL to nL) picodroplets. 

View Portfolio